MX2012000034A - Metodos para el tratamiento o la prevencion de la fatiga. - Google Patents

Metodos para el tratamiento o la prevencion de la fatiga.

Info

Publication number
MX2012000034A
MX2012000034A MX2012000034A MX2012000034A MX2012000034A MX 2012000034 A MX2012000034 A MX 2012000034A MX 2012000034 A MX2012000034 A MX 2012000034A MX 2012000034 A MX2012000034 A MX 2012000034A MX 2012000034 A MX2012000034 A MX 2012000034A
Authority
MX
Mexico
Prior art keywords
treating
methods
preventing fatigue
fatigue
preventing
Prior art date
Application number
MX2012000034A
Other languages
English (en)
Spanish (es)
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Susan Marie Melnick
Duncan Taylor
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2012000034A publication Critical patent/MX2012000034A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012000034A 2009-06-22 2010-06-21 Metodos para el tratamiento o la prevencion de la fatiga. MX2012000034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (1)

Publication Number Publication Date
MX2012000034A true MX2012000034A (es) 2012-02-21

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000034A MX2012000034A (es) 2009-06-22 2010-06-21 Metodos para el tratamiento o la prevencion de la fatiga.

Country Status (13)

Country Link
US (5) US8741950B2 (show.php)
EP (1) EP2445490B1 (show.php)
JP (3) JP6095366B2 (show.php)
KR (3) KR102173587B1 (show.php)
CN (2) CN106727486A (show.php)
AU (1) AU2010270971B2 (show.php)
BR (1) BRPI1015233A2 (show.php)
CA (1) CA2765463C (show.php)
IN (1) IN2012DN00624A (show.php)
MX (1) MX2012000034A (show.php)
RU (1) RU2567801C2 (show.php)
TW (1) TWI453014B (show.php)
WO (1) WO2011005473A2 (show.php)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101335941B1 (ko) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
CN106727486A (zh) 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
RU2014113967A (ru) * 2011-12-21 2016-02-10 Хербал Пауэрс Корпорейшн Комбинированная терапия рассеянного склероза интерфероном и андрографолидами
SI2968208T1 (sl) 2013-03-13 2023-02-28 Jazz Pharmaceuticals Ireland Limited, Zdravljenje katapleksije
KR20210152011A (ko) * 2013-07-12 2021-12-14 에스케이바이오팜 주식회사 금연의 촉진
WO2015010014A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
AU2014345539B2 (en) * 2013-11-08 2020-04-23 Legacy Healthcare (Switzerland) Sa Method for the management of cancer and treatment of cancer comorbidities
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3509582B1 (en) 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
JP2020514465A (ja) * 2016-12-30 2020-05-21 ドンジン セミケム カンパニー リミテッドDongjin Semichem Co., Ltd. コーティング組成物およびこれから製造されるフィルム
WO2018222954A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals International Iii Limited Methods and compositions for treating excessive sleepiness
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
KR20240101826A (ko) * 2021-11-16 2024-07-02 액섬 몰타 엘티디. 인지 장애를 치료하기 위한 방법 및 조성물
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285829B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015626A2 (en) 1996-10-08 1998-04-16 Institute Of Child Health Mutant ciita molecule and uses thereof
CN1076016C (zh) * 1996-10-10 2001-12-12 Sk株式会社 O-氨基甲酰基-苯丙胺醇化合物、其药学上有用的盐和它们的制备方法
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
AU2005302589B2 (en) * 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
KR101335941B1 (ko) * 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
EA019935B1 (ru) 2005-07-26 2014-07-30 Янссен Фармацевтика Н.В. Способы лечения алкогольной абстиненции
AU2007313017A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
CN106727486A (zh) * 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
SI2968208T1 (sl) * 2013-03-13 2023-02-28 Jazz Pharmaceuticals Ireland Limited, Zdravljenje katapleksije
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Also Published As

Publication number Publication date
US10507192B2 (en) 2019-12-17
US9999609B2 (en) 2018-06-19
WO2011005473A2 (en) 2011-01-13
EP2445490A2 (en) 2012-05-02
EP2445490A4 (en) 2019-10-23
EP2445490B1 (en) 2023-02-08
KR102173587B1 (ko) 2020-11-04
US8741950B2 (en) 2014-06-03
US20140243406A1 (en) 2014-08-28
JP2015214564A (ja) 2015-12-03
AU2010270971A1 (en) 2012-01-19
BRPI1015233A2 (pt) 2018-02-20
US20170000756A1 (en) 2017-01-05
JP6095366B2 (ja) 2017-03-15
US20120142769A1 (en) 2012-06-07
US9464041B2 (en) 2016-10-11
JP2012530779A (ja) 2012-12-06
KR20190105675A (ko) 2019-09-17
CN106727486A (zh) 2017-05-31
US20180263950A1 (en) 2018-09-20
IN2012DN00624A (show.php) 2015-06-12
WO2011005473A9 (en) 2011-05-12
JP6368285B2 (ja) 2018-08-01
TWI453014B (zh) 2014-09-21
RU2012101947A (ru) 2013-07-27
KR20120098578A (ko) 2012-09-05
AU2010270971B2 (en) 2015-08-20
CN102481274A (zh) 2012-05-30
RU2567801C2 (ru) 2015-11-10
KR102021075B1 (ko) 2019-11-04
JP2018188450A (ja) 2018-11-29
CA2765463A1 (en) 2011-01-13
TW201105320A (en) 2011-02-16
US20200061017A1 (en) 2020-02-27
KR20170086710A (ko) 2017-07-26
CA2765463C (en) 2018-10-09

Similar Documents

Publication Publication Date Title
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
MY169328A (en) Compositions for the treatment of dry eye
WO2011020061A3 (en) Compositions and methods of for treating bipolar disorder
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MY160894A (en) Oligosaccharide composition for treating skin diseases
AU2011328009A8 (en) Compounds and methods for treating pain
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MY172372A (en) Compositions and methods for lowering triglycerides
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
TNSN08400A1 (en) Organic compounds and their uses
IN2012DN02471A (show.php)
WO2013098416A3 (fr) Composes anti-douleur
TN2015000255A1 (fr) Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX2009009693A (es) Metodos para activar irs-1 y akt.
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
EP3449917A3 (en) Tapentadol for preventing chronification of pain
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.

Legal Events

Date Code Title Description
FG Grant or registration